State of Alaska Department of Revenue Grows Holdings in Gilead Sciences, Inc. (GILD)

State of Alaska Department of Revenue grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1,717.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 128,498 shares of the biopharmaceutical company’s stock after acquiring an additional 121,428 shares during the period. State of Alaska Department of Revenue’s holdings in Gilead Sciences were worth $9,203,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of GILD. Truepoint Inc. bought a new stake in Gilead Sciences in the second quarter worth approximately $204,000. Tocqueville Asset Management L.P. boosted its holdings in shares of Gilead Sciences by 2.2% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 35,133 shares of the biopharmaceutical company’s stock worth $2,487,000 after buying an additional 757 shares during the period. Van Cleef Asset Management Inc boosted its holdings in shares of Gilead Sciences by 3.0% during the 2nd quarter. Van Cleef Asset Management Inc now owns 65,548 shares of the biopharmaceutical company’s stock worth $4,639,000 after buying an additional 1,927 shares during the period. One Capital Management LLC boosted its holdings in shares of Gilead Sciences by 10.8% during the 2nd quarter. One Capital Management LLC now owns 28,653 shares of the biopharmaceutical company’s stock worth $2,028,000 after buying an additional 2,794 shares during the period. Finally, GAM Holding AG boosted its holdings in shares of Gilead Sciences by 5.4% during the 2nd quarter. GAM Holding AG now owns 899,769 shares of the biopharmaceutical company’s stock worth $63,686,000 after buying an additional 46,046 shares during the period. 75.71% of the stock is owned by institutional investors.

In other news, Chairman John C. Martin sold 50,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the transaction, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. In the last 90 days, insiders sold 432,768 shares of company stock valued at $33,919,138. Corporate insiders own 1.30% of the company’s stock.

GILD has been the subject of several recent analyst reports. Mizuho upped their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, December 11th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective for the company. in a report on Wednesday, January 17th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $87.04.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.69 on Thursday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The stock has a market cap of $105,729.42, a price-to-earnings ratio of 23.19, a PEG ratio of -1.85 and a beta of 1.22. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the prior year, the company posted $2.70 EPS. The business’s revenue was down 18.7% on a year-over-year basis. sell-side analysts forecast that Gilead Sciences, Inc. will post 6.24 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio is currently 59.77%.

WARNING: This piece was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://weekherald.com/2018/02/22/state-of-alaska-department-of-revenue-grows-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply